NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), announced today that its PGxHealth® division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy (CD-DCM) and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases. The Company also announced the introduction of a significantly enhanced Brugada Syndrome (BrS) test, which now includes seven BrS-causative genes. In addition to these new test offerings, PGxHealth’s FAMILION tests will be featured in several scientific presentations at the annual Heart Rhythm Society meeting. By expanding and enhancing the FAMILION family of tests, PGxHealth continues to help guide treatment that may prevent possible sudden cardiac death.
